Stephen L. Spotts
Mr. Spotts is a Director, having been elected in 2010. He is chief executive officer, president, director and founder of ProTom International, Inc., a medical technology company focused on proton therapy for cancer patients. Before founding ProTom in 2007, from 2000 to 2006, Mr. Spotts was president, chief executive officer, and a member of the board of directors of Pathology Partners, Inc. (now Inform Diagnostics). From 2005 through mid-2008, he served on the board of directors of Genoptix, Inc., a California-based, publicly-traded specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists; Genoptix, Inc. was acquired by Novartis AG in 2011. Mr. Spotts earned his bachelor’s degree in Business Administration from the University of Mississippi.